International Stem Cell Corporation reports $2.4 million product revenue for Q3 2025
International Stem Cell Corporation reported product sales of $2.4 million for the three months ended September 30, 2025, up 9% from $2.2 million in the same period in 2024. For the nine months ended September 30, 2025, product sales were $6.9 million compared to $6.6 million for the prior year period. Net income for the quarter was $57 thousand, compared to a net loss of $125 thousand in the same quarter last year. The increase in product sales was attributed to growth in the Biomedical market segment, particularly from cells and other product sales, partially offset by decreases in media product sales and in the skin care product line. The company reported no revenue generated from its principal therapeutic and clinical product development operations during the period.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. International Stem Cell Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-25-280090), on November 13, 2025, and is solely responsible for the information contained therein.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。